Tıp Fakültesi / Faculty of Medicine
Permanent URI for this collectionhttps://hdl.handle.net/11727/1403
Browse
8 results
Search Results
Item Characteristics and Outcomes of Myelodysplastic Syndrome Patients Treated With Darbepoetin Alfa for Anemia in Turkey: A Multicenter Retrospective Study(CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023) Acar, Ibrahim Halil; Atalay, Figen; Demirsoy, Esra Terzi; Can, Ferda; Guven, Zeynep Tugba; Cetiner, Mustafa; Tombak, Anil; Comert, Melda; Guvenc, BirolItem Relationship of P-Selectin Glycoprotein Ligand-1 to Prognosis in Patients with Multiple Myeloma(2015) Atalay, Figen; Atesoglu, Elif Birtas; Yildiz, Semsi; Firath-Tuglular, Tulin; Karakus, Sema; Bayik, Mahmut; 0000-0003-4384-2913; 0000-0001-7615-4581; 25445472; B-5507-2014; W-9092-2019The aim of the present study was to investigate the relationship between PSGL-1 expression in the bone marrow and the known prognostic factors for multiple myeloma disease, disease stage, and survival. D162 staining and the staining degree, with the other standard immunohistochemical stains, were shown to be beneficial in the diagnosis of multiple myeloma disease. However, the results did not provide information about the disease course. Background: Changes occur in adhesion molecules in the disease course of multiple myeloma. P-selectin glycoprotein ligand-1 (PSGL-1, CD162) works as the ligand of selectin-neutrophil adhesion molecules. The aim of the present study was to investigate the relationship between PSGL-1 expression in the bone marrow and the known prognostic factors for multiple myeloma disease, disease stage, and survival. Materials and Methods: This research included 63 patients with multiple myeloma (26 women [41.3%]; 37 men [58.7%]). The bone marrow biopsy samples obtained at disease diagnosis for each patient were stained imniunohistochemically in terms of CD162 expression using standard diagnostic immunohistochemical staining methods. The laboratory results, CD162 expression, overall survival, demographic characteristics of the disease, and the relationship between CD162 expression and the disease stage were evaluated. Results: Among the 63 patients included in the present study, the survival rate was 82.3% for 1 year, 73.2% for 2 years, 63.4% for 3 years, 51.7% for 4 years, 40.3% for 5 years, and 33.6% for 6 and 7 years. A statistically significant difference was not detected between the CD162 staining ratio and disease survival (P = .232). A statistically significant difference was not detected between the CD162 staining degree and survival rate (P = .184). However, the overall survival of the patients with no CD162 expression in the bone marrow was lower than that for the patients whose CD162 was stained 1, 2, and 3 degrees (12.33 +/- 11.49, 28.65 +/- 31.44, 37.25 +/- 29.32, and 47.92 +/- 45.29 months, respectively; P < .001). Conclusion: In the present study, CD162 staining and the staining degree, with the other standard immunohistochemical stains, were shown to be beneficial in the diagnosis of multiple myeloma disease. However, the results did not provide information about the disease course. Studies of a larger number of patients to examine P-selectin and interleukin-6 levels are needed to investigate the disease course.Item Treatment of Patients with Multiple Myeloma Over 65 Yr: More Tolerability or Better Response?(2015) Tarkun, Pinar; Atalay, Figen; Atesoglu, Elif Birtas; Mehtap, Ozgur; Simsek, Melih; Terzi, Esra; Geduk, Ayfer; Balli, Fatih; Batman, Adnan; Baydemir, Canan; Hacihanefioglu, Abdullah; 0000-0003-4384-2913; 25220635; B-5507-2014ObjectiveTwo-thirds of newly diagnosed patients with multiple myeloma (MM) are over 65yr and/or physically unfit. Such patients are not eligible for high-dose chemotherapy or stem cell transplantation. The treatment aims in these patients should be to prolong survival by obtaining the best possible response, while maintaining good tolerability. The aim of our study was to evaluate the response to treatment and treatment-related toxicities in patients treated with conventional and novel protocols. MethodsThe records of 138 elderly (65yr) patients with MM were retrospectively evaluated. ResultsThe median overall survival(OS) of the patients was 46months. The median progression-free survival (PFS) was 18months. The OS and PFS of the patients treated with the conventional protocols did not differ significantly from those treated with the novel protocols. The statistical analysis of the quality of the response to the treatment with the conventional and novel therapies showed that complete remission (CR), combined with a very good partial response (VGPR), was significantly higher in the latter. However, the toxicities were higher in the novel treatment group. ConclusionThe novel drug protocols significantly increased the quality of the responses of elderly patients with MM to therapy, but they did not increase the patients' tolerability.Item Successful Treatment with Bortezomib and Dexamethasone Combination in A Patient with Monoclonal Gammopathy of Renal Significance(2018) Atalay, Figen; https://orcid.org/0000-0003-4384-2913; B-5507-2014A 40-year-old woman was reported to the nephrology outpatient clinic because of sudden-onset hypertensive attack, massive proteinuria, and high levels of creatinine. She had no previous medical history. Membranoproliferative glomerulonephritis and monoclonal. light chain staining was seen on renal biopsy. She was evaluated for plasma cell diseases in hematology clinic. She was diagnosed as having monoclonal gammopathy of renal significance. Six courses of bortezomib plus dexamethasone were given to her. After this treatment schedule, her renal dysfunction and hypertension were resolved. Monoclonal gammopathy of renal significance is a disease caused by monoclonal immunoglobulins secreted by clonal B cells. Monoclonal gammopathy of renal significance should be considered with any unexplained renal impairment or proteinuria. Hematology department must be consulted as well. If treatment is delayed, permanent kidney damage can occur. (c) 2018 The Egyptian Journal of HaematologyItem Acute Coronary Syndrome Associated with Carfilzomib Treatment(2020) Kocabas, Umut; Atalay, Figen; Altay, Hakan; Altun, Armagan; Pehlivanoglu, Seckin; 0000-0003-4384-2913; 0000-0002-8506-7583; 0000-0002-3233-8263; 32647445; AAE-1392-2021; B-5507-2014; ABB-5844-2020Item GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin's lymphoma.(2019) Ertan-Ahmed, Senem; Kiehl, Michael G.; Radinoff, Atanas; Graklanov, Vasko; Tzvetkov, Nikolay; Mihaescu, Rodica; Ozatli, Duzgun; Atalay, Figen; Turgut, Burhan; Cho, Seok-Gu; Rekhtman, Grygoriy; Sahin, Adem; Oncel, Hatice; Choi, Yuri; Yang, Sang-In; Choi, Yoon-Jeong; Heo, MinKyu; Sung, Young ChulItem The Effect of PET/CT Deauville Criteria on Progression Free Survival and Overall Survival in Multiple Myeloma Patients Following Autologous Stem Cell Transplantation(2019) Tuglular, Tulin; Sahin, Eren; Ones, Tunc; Atalay, Figen; Atesoglu, Elif Birtas; Menguc, Meral Ulukoylu; Atagunduz, Isik Kaygusuz; Toptas, Tayfur; B-5507-2014Item Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey(2019) Beksac, Meral; Seval, Guldane Cengiz; Paydas, Semra; Tuglular, Tulin Firatli; Arslan, Onder; Goker, Hakan; Kaynar, Leylagul; Altuntas, Fevzi; Atalay, Figen; Teke, Havva Uskudar; Bolaman, Ali Zahit; Pehlivan, Mustafa; Sonmez, Mehmet; Demir, Ahmet Muzaffer; Topcuoglu, Pervin; Yilmaz, Mehmet; Kabukcu, Sibel Hacioglu; Albayrak, Murat; Yurttas, Nurgul Ozer; Salihoglu, Ayse; Cakar, Merih Kizil; Gurman, Gunhan